The FDA has approved Affymetrix's in vitro gene expression-based cancer diagnostic testing system. Pathwork Diagnostics, a member of the Powered by Affymetrix program, also got regulatory clearance for its Pathwork Tissue of Origin Test. The products can "potentially improve cancer diagnostics and subsequent treatment planning and outcome," Affymetrix's president said.

Related Summaries